Combined therapy with epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer

Area of Science:

• Oncology
• Pharmacology
• Genetics

Background:

• Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) offer clinical benefits for advanced non-small cell lung cancer (NSCLC) with EGFR mutations.
• Acquired resistance to EGFR-TKIs is inevitable, necessitating novel therapeutic strategies.
• The efficacy of EGFR-TKIs in locally advanced NSCLC requires further clarification.

Purpose of the Study:

• To review recent advancements in combination therapies involving EGFR-TKIs and chemotherapy or radiotherapy for NSCLC patients with EGFR mutations.
• To assess the potential of combination treatments in overcoming EGFR-TKI resistance.

Main Methods:

• Literature review of clinical studies on combination treatments for EGFR-mutated NSCLC.
• Analysis of patient selection criteria and their impact on treatment outcomes.

Main Results:

• Early combination therapy studies lacked patient selection, yielding no clear clinical benefit.
• Recent clinical studies incorporating patient selection based on EGFR mutation status demonstrate promising results.
• Combination therapies are under active investigation in ongoing clinical trials.

Conclusions:

• Combination therapy with EGFR-TKIs and other modalities shows potential for treating EGFR-mutated NSCLC.
• Patient selection based on EGFR mutation status is crucial for the success of combination therapies.
• This approach may eventually supersede current standard treatments for this patient group.